Efficacy and Safety of Glecaprevir/Pibrentasvir Combination Therapy for Patients with Genotype 2 Chronic Hepatitis C Infection Who Failed HCV Eradication by SOF+RBV Treatment

Abstract

Although sofosbuvir plus ribavirin (SOF+RBV) treatment is highly effective for genotype 2 chronic hepatitis C infection, 3%-7% of patients failed to achieve a sustained virologic response (SVR). As the optimal combination of direct-acting antivirals remains unclear, we conducted a multicenter trial using 12-week Glecaprevir/Pibrentasvir (GLE/PIB) therapy for patients who failed to achieve an SVR by SOF+RBV treatment. We encountered 13 patients; 9 men and 4 women. Of 13 patients, 10 were genotype 2a and 3 were genotype 2b. The rates of rapid virologic response, expected treatment response, and SVR12 were 92.3%, 100%, and 100%, respectively. Adverse events were observed in 4 cases (30.8%), which were mild events. In conclusion, 12-week GLE/PIB therapy is highly effective for patients who did not achieve SVR by SOF+RBV treatment.